Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges: 2014-2025

Historic Amortization of Deferred Charges for Ani Pharmaceuticals (ANIP) over the last 11 years, with Sep 2025 value amounting to $340,000.

  • Ani Pharmaceuticals' Amortization of Deferred Charges rose 180.99% to $340,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 24.80%. This contributed to the annual value of $642,000 for FY2024, which is 83.63% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $340,000 for Q3 2025, which was down 0.29% from $341,000 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $998,000 in Q4 2022 and a low of $102,000 during Q1 2024.
  • In the last 3 years, Ani Pharmaceuticals' Amortization of Deferred Charges had a median value of $341,000 in 2025 and averaged $478,455.
  • Per our database at Business Quant, Ani Pharmaceuticals' Amortization of Deferred Charges tumbled by 89.67% in 2024 and then surged by 217.65% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $794,000 in 2021, then grew by 25.69% to $998,000 in 2022, then fell by 4.61% to $952,000 in 2023, then plummeted by 66.07% to $323,000 in 2024, then soared by 180.99% to $340,000 in 2025.
  • Its Amortization of Deferred Charges stands at $340,000 for Q3 2025, versus $341,000 for Q2 2025 and $324,000 for Q1 2025.